DUBLIN–(BUSINESS WIRE)–The “Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2021, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.
Report Highlights
Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 7, 11, 7, 2, 43, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 3, 2, 12 and 2 molecules, respectively.
Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Influenza A Virus, H1N1 Subtype Infections – Overview
- Influenza A Virus, H1N1 Subtype Infections – Therapeutics Development
- Influenza A Virus, H1N1 Subtype Infections – Therapeutics Assessment
- Influenza A Virus, H1N1 Subtype Infections – Companies Involved in Therapeutics Development
- Influenza A Virus, H1N1 Subtype Infections – Drug Profiles
- Influenza A Virus, H1N1 Subtype Infections – Dormant Projects
- Influenza A Virus, H1N1 Subtype Infections – Discontinued Products
- Influenza A Virus, H1N1 Subtype Infections – Product Development Milestones
- Appendix
Companies Mentioned
- AbbVie Inc
- Abzyme Therapeutics LLC
- Adimmune Corp
- Akshaya Bio Inc
- Alla Chem LLC
- Allergy Therapeutics Plc
- AlphaVax Inc
- Altimmune Inc
- Ansun Biopharma Inc
- AstraZeneca Plc
- AVM Biotechnology LLC
- BioTherapeutics Inc
- Blue Water Vaccines Inc
- BlueWillow Biologics Inc
- Brandenburg Antiinfektiva GmbH
- BunyaVax BV
- CEL-SCI Corp
- Celestial Therapeutics Inc
- Changchun Bcht Biotechnology Co Ltd
- Chicago Biosolutions Inc
- CHO Pharma Inc
- Cidara Therapeutics Inc
- Cilian AG
- Cocrystal Pharma Inc
- CSL Ltd
- Curevac NV
- CytoAgents Inc
- Cytocom Inc
- Dnarx LLC
- Emergent BioSolutions Inc
- Ena Respiratory Pty Ltd
- Ena Therapeutics Pty Ltd
- EpiVax Inc
- Etubics Corp
- ExpreS2ion Biotech Holding AB
- FluGen Inc
- Gamma Vaccines Pty Ltd
- Genentech USA Inc
- GlaxoSmithKline Plc
- Greffex Inc
- ILiAD Biotechnologies LLC
- Imutex Ltd
- Inovio Pharmaceuticals Inc
- Institute of Virology Vaccines and Sera Torlak
- InvVax Inc
- Jiangsu Ab&b Biotechnology Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- Johnson & Johnson
- Liaoning Cheng Da Biotechnology Co Ltd
- Medicago Inc
- Microbiotix Inc
- NanoViricides Inc
- New Amsterdam Sciences Inc
- Novavax Inc
- NuGenerex Immuno-Oncology Inc
- PeptiDream Inc
- Pneumagen Ltd
- Recce Pharmaceuticals Ltd
- Replikins Ltd
- Revelation Biosciences Inc
- SAB Biotherapeutics Inc
- Sanofi
- Sciogen Inc
- Seqirus Ltd
- Serum Institute of India Pvt Ltd
- Shanghai Institute of Biological Products Co Ltd
- Sonnet BioTherapeutics Holdings Inc
- TechnoVax Inc
- Tiba Biotech LLC
- Trellis Bioscience Inc
- UMN Pharma Inc
- Vaccibody AS
- Vacthera BioTech GmbH
- Vaxart Inc
- Vaxxas Inc
- Viramatix Sdn Bhd
- Virion Biotherapeutics
- Vironova Medical AB
- Vivaldi Biosciences Inc
For more information about this report visit https://www.researchandmarkets.com/r/5l58j5
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900